Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 238Carcinoma, Non-Small-Cell Lung 205Prostatic Neoplasms 137Lung Neoplasms 96Stomach Neoplasms 85Head and Neck Neoplasms 59Squamous Cell Carcinoma of Head and Neck 58Neoplasms 42Neoplasm Metastasis 39Esophageal Neoplasms 36Ovarian Neoplasms 29Pancreatic Neoplasms 27Sarcoma 19Urinary Bladder Neoplasms 18Adenocarcinoma of Lung 18Carcinoma, Squamous Cell 17Triple Negative Breast Neoplasms 15Nasopharyngeal Carcinoma 14Adenocarcinoma 14Carcinoma, Ovarian Epithelial 13Adenocarcinoma Of Esophagus 13Recurrence 12Inflammatory Breast Neoplasms 10Carcinoma, Transitional Cell 10Breast Neoplasms, Male 10Esophageal Squamous Cell Carcinoma 9Laryngeal Neoplasms 8Uterine Cervical Neoplasms 7Nasopharyngeal Neoplasms 7Leiomyosarcoma 7

Interventions

camrelizumab 2apatinib 2S 1 (combination) 1Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Metastatic Gastric Adenocarcinoma × Docetaxel × Clear all
NCT04781686 2021-05-17

Apatinib Plus Camrelizumab Combined With Docetaxel and S1 in First-line Treatment for Metastatic Gastric Cancer

Zhongnan Hospital

Phase 2 Unknown
35 enrolled
Gastrointestinal

Metastatic Gastric Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡